Drugs / d-lysergic acid diethylamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05976698 | Feb 2024 → Feb 2025 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-lysergic acid diethylamide | “The aim of the study is to characterize the effects of low doses of LSD (d-lysergic acid diethylamide) on behavioral and neural indicators of feedback and feedforward signaling...” NCT05976698 ↗ |
| Known as | LSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05976698 ↗ |
| Route | Oral | “administered 10 μg LSD per os” NCT05976698 ↗ |